Christopher R. Leon Guerrero

Christopher R. Leon Guerrero

Auto-generated profile, based on publicly available information

Christopher R. Leon Guerrero

Department of Neurology, Atrium Health, Charlotte, NC (C.R.L.G.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
SYShadi Yaghi
Shadi Yaghi
LSLiqi Shu
Liqi Shu
EBEkaterina Bakradze
Ekaterina Bakradze
SOSetareh Salehi Omran
Setareh Salehi Omran
JGJames Anthony Giles
James Anthony Giles
KFKaren Furie
Karen Furie
Background: A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort. Methods: This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020. We abstracted demographics and CVT risk factors, hypercoagulable labs, baseline imaging data, and clinical and radiological outcomes from medical records. We used adjusted inverse probability of treatment weighted Cox-regression models to compare recurrent cerebral or systemic venous thrombosis, death, and major hemorrhage in patients treated with warfarin versus DOACs. We performed adjusted inverse probability of treatment weighted logistic regression to compare recanalization rates on follow-up imaging across the 2 treatments groups. Results: Among 1025 CVT patients across 27 centers, 845 patients met our inclusion criteria. Mean age was 44.8 years, 64.7% were women; 33.0% received DOAC only, 51.8% received warfarin only, and 15.1% received both treatments at different times. During a median follow-up of 345 (interquartile range, 140–720) days, there were 5.68 recurrent venous thrombosis, 3.77 major hemorrhages, and 1.84 deaths per 100 patient-years. Among 525 patients who met recanalization analysis inclusion criteria, 36.6% had complete, 48.2% had partial, and 15.2% had no recanalization. When compared with warfarin, DOAC treatment was associated with similar risk of recurrent venous thrombosis (aHR, 0.94 [95% CI, 0.51–1.73]; P =0.84), death (aHR, 0.78 [95% CI, 0.22–2.76]; P =0.70), and rate of partial/complete recanalization (aOR, 0.92 [95% CI, 0.48–1.73]; P =0.79), but a lower risk of major hemorrhage (aHR, 0.35 [95% CI, 0.15–0.82]; P =0.02). Conclusions: In patients with CVT, treatment with DOACs was associated with similar clinical and radiographic outcomes and favorable safety profile when compared with warfarin treatment. Our findings need confirmation by large prospective or randomized studies.

1 December 2015 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
SYShadi Yaghi
Shadi Yaghi
ABAmelia K. Boehme
Amelia K. Boehme
JDJamil Dibu
Jamil Dibu
CGChristopher R. Leon Guerrero
Christopher R. Leon Guerrero
SASyed Ali
Syed Ali
JWJoshua Z. Willey
Joshua Z. Willey
Quiz Ref ID Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) improves the outcome of patients with ischemic stroke treated within 4½ hours after symptom onset.1 The most serious complication is symptomatic intracerebral hemorrhage (sICH), which was reported in 6% of patients with acute ischemic stroke in the National Institute of Neurological Disorders and Stroke rtPA trials.2 Quiz Ref ID Despite its infrequent occurrence, sICH is associated with significant morbidity and a high mortality rate approaching 50%.2 Recommendations by the American Heart Association and the American Stroke Association for the management of sICH are to replace coagulation factors with cryoprecipitate and to transfuse with platelets.1 While prior studies3-7 have investigated clinical and imaging risk factors for sICH, to our knowledge, the efficacy of these treatment recommendations has been examined in few investigations, which have been largely single-center studies.8 Prior evidence has shown substantial variability in treatment practices and limited success in halting sICH.8 These studies are limited by small sample sizes and incomplete accounting for confounders, such as code status change after sICH diagnosis. Therefore, we pooled contemporary data on treatment practices across several high-volume stroke centers in the United States with the objective to study the natural history of thrombolysis-related sICH, with a particular focus on the potential efficacy of various treatments. We also sought to identify key variables in the acute stroke treatment period that contributed to a high in-hospital mortality rate.

1 April 2024 in Stroke
Verified
Journal Article
Closed access
SYShadi Yaghi
Shadi Yaghi
LSLiqi Shu
Liqi Shu
DMDaniel Mandel
Daniel Mandel
CGChristopher R. Leon Guerrero
Christopher R. Leon Guerrero
NHNils Henninger
Nils Henninger
KFKaren Furie
Karen Furie
BACKGROUND: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation. METHODS: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments. RESULTS: The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45–1.12]; P =0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28–2.24]; P =0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35–5.45]; P =0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53–20.13]; P =0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18–0.88]; P interaction =0.009). CONCLUSIONS: Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.

9 October 2008 in Annals of Human Genetics
Verified
Journal Article
Closed access
PDF file
SZS. Züchner
S. Züchner
JGJ. R. Gilbert
J. R. Gilbert
EME. R. Martin
E. R. Martin
CLC. R. Leon‐Guerrero
C. R. Leon‐Guerrero
PXP.‐T. Xu
P.‐T. Xu
MPM. A. Pericak‐Vance
M. A. Pericak‐Vance

19 July 2016 in Neurology
Verified
Journal Article
Closed access
PDF file
CGChristopher R. Leon Guerrero
Christopher R. Leon Guerrero
SPSheel Pathak
Sheel Pathak
DGDorothy K. Grange
Dorothy K. Grange
GSGautam K. Singh
Gautam K. Singh
CNColin G. Nichols
Colin G. Nichols
KVKatie D. Vo
Katie D. Vo
Objective: To describe the neurologic and neuroimaging manifestations associated with Cantú syndrome. Methods: We evaluated 10 patients with genetically confirmed Cantú syndrome. All adult patients, and pediatric patients who were able to cooperate and complete the studies, underwent neuroimaging, including vascular imaging. A salient neurologic history and examination was obtained for all patients. Results: We observed diffusely dilated and tortuous cerebral blood vessels in all patients who underwent vascular imaging. White matter changes were observed in all patients who completed an MRI brain study. Two patients had a persistent trigeminal artery. One patient had an occluded right middle cerebral artery. One patient had transient white matter changes suggestive of posterior reversible encephalopathic syndrome. Four patients had migraines with one patient having complicated migraines. Seizures were seen in early life but infrequent. The majority of patients had mild developmental delays and one patient had a diagnosis of autism. Conclusions: Cantú syndrome is associated with various neurologic manifestations, particularly cerebrovascular findings including dilated and tortuous cerebral vessels, white matter changes, and persistent fetal circulation. Involvement of the KATP SUR2/Kir6.1 subtype potentially plays an important role in the neurologic manifestations of Cantú syndrome.

1 August 2020 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
MAMohanad AlGaeed
Mohanad AlGaeed
MGManjot Grewal
Manjot Grewal
PRPerry K. Richardson
Perry K. Richardson
CGChristopher R. Leon Guerrero
Christopher R. Leon Guerrero